Sweden · Delayed Price · Currency is SEK Swedencare AB Earnings Call Transcripts
Fiscal Year 2026
-
Double-digit organic growth and record gross margin were achieved, driven by strong European and online sales, while North America stabilized and production segments rebounded. Major new contracts, product launches, and operational efficiencies support a positive outlook for 2026.
-
Stable demand and improved operational efficiency are driving higher margins and profitability, with strong growth in North America, Europe, and contract manufacturing. Walmart and Amazon channels show positive trends, and cost headwinds remain limited.
Fiscal Year 2025
-
Q4 2025 saw strong organic growth but disappointing profitability due to one-off costs, marketing overspend, and inventory write-offs. Improved cost controls, new product launches, and a focus on pharma and online channels are expected to drive margin recovery and growth in 2026.
-
Record Q3 revenue and EBITDA were achieved, driven by strong growth in North America and Europe, major US retail expansion, and robust online sales. Outlook remains positive with double-digit growth and margin improvement expected, despite some margin pressure from marketing investments.
-
Q2 2025 saw 3% sales growth and 7% organic growth, with margins impacted by the Amazon transition and delayed Walmart order. H2 is expected to deliver double-digit growth and improved profitability, driven by new launches, online momentum, and operational efficiencies.
-
Q1 2025 saw 7% revenue growth and a 19.4% EBITDA margin, with strong cash flow and stable gross margin. Strategic acquisitions and new retail partnerships are set to drive double-digit organic growth for the full year, with margin improvements expected as costs normalize.
Fiscal Year 2024
-
Q4 2024 delivered record sales and EBITDA, though organic growth lagged at 4% due to NaturVet's decline. Dental and pharma segments excelled, with strong European and online performance. Outlook for 2025 is positive, with NaturVet expected to rebound and further margin improvements anticipated.
-
Q3 saw 9% organic growth, with strong performance in Europe and online channels, but NaturVet's decline weighed on North America. Gross margin improved to 58%, EBITDA margin dipped due to higher marketing spend, and net debt/EBITDA fell to 2.2. 2025 is expected to bring stronger growth as new retail channels and online initiatives ramp up.
-
Q2 2024 saw 10% organic growth, record sales, and margin improvement, despite softness in the veterinary channel and NaturVet brand. Strategic acquisitions, strong online and European performance, and improved inventory management are expected to drive double-digit growth and higher profitability in H2.